Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Common Equity: 2011-2025

Historic Common Equity for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $70.7 million.

  • Niagen Bioscience's Common Equity rose 105.64% to $70.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.7 million, marking a year-over-year increase of 105.64%. This contributed to the annual value of $46.1 million for FY2024, which is 61.98% up from last year.
  • Latest data reveals that Niagen Bioscience reported Common Equity of $70.7 million as of Q3 2025, which was up 10.10% from $64.2 million recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Common Equity registered a high of $70.7 million during Q3 2025, and its lowest value of $20.8 million during Q2 2022.
  • Its 3-year average for Common Equity is $40.1 million, with a median of $30.7 million in 2024.
  • As far as peak fluctuations go, Niagen Bioscience's Common Equity plummeted by 50.70% in 2022, and later spiked by 108.98% in 2025.
  • Niagen Bioscience's Common Equity (Quarterly) stood at $31.7 million in 2021, then dropped by 9.63% to $28.7 million in 2022, then dropped by 0.75% to $28.5 million in 2023, then surged by 61.98% to $46.1 million in 2024, then spiked by 105.64% to $70.7 million in 2025.
  • Its Common Equity stands at $70.7 million for Q3 2025, versus $64.2 million for Q2 2025 and $55.3 million for Q1 2025.